Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Pharma Lobby Says Delhi High Court Exceeded Its Authority In Restraining Hetero Dasatinib Application Due To BMS Petition

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The recent decision of the Delhi High Court restraining the Drug Controller General of India from approving Hetero's dasatinib has drawn flak from the Indian Pharmaceutical Alliance - a group that represents the most influential Indian drug companies. The court had barred India's drug regulatory agency from approving Hetero's application on a petition filed by Bristol-Myers Squibb, maker of the brand drug Sprycel

You may also be interested in...



Cipla Challenges Delhi Court’s Decision Restraining India’s Drug Controller From Granting Marketing Nod For Sorafenib

MUMBAI - Indian drug companies are mounting a strong opposition against ex-parte judgements passed by Indian courts restraining the Drug Controller General of India from processing marketing approvals of their drugs

Cipla Challenges Delhi Court’s Decision Restraining India’s Drug Controller From Granting Marketing Nod For Sorafenib

MUMBAI - Indian drug companies are mounting a strong opposition against ex-parte judgements passed by Indian courts restraining the Drug Controller General of India from processing marketing approvals of their drugs

On BMS’ Plea, Delhi Court Nixes Hetero’s Dasatinib Application; Directs India’s Drug Controller To Examine Patent Violations

MUMBAI - In a decision that could have a far-reaching impact on drug patent cases in India, the Delhi High Court has directed the Drug Controller General of India to monitor for patent infringements by any party while a drug's approval application is scrutinized

Related Content

UsernamePublicRestriction

Register

SC069783

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel